Vimarsana
Biggest News Aggregation in the World

Page 3 - Devon Christie News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Devon Christie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Devon Christie Today - Breaking & Trending Today

Numinus Wellness Inc. congratulates MAPP1 trial study team on announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD) - Vimarsana News

Numinus Wellness Inc. congratulates MAPP1 trial study team on announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD)

 Numinus Wellness congratulates study team on announcement of results from Phase 3 randomized clinical trial of MDMA-assisted therapy for treatment of severe PTSD The trial, which involved 90 participants with chronic PTSD, demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with 67% no longer qualifying for PTSD diagnosis in comparison to 32% of participants randomized to placebo The results, published in the peer-reviewed medical journal Nature Medicine, pr...

Non-Traditional Therapies Could Fill Vital Mental Health Needs - Vimarsana News

Non-Traditional Therapies Could Fill Vital Mental Health Needs

Non-Traditional Therapies Could Fill Vital Mental Health Needs - FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, March 2, 2021 /PRNewswire/ -- Non-traditional therapies are coming a long way from their stigmatized roots. Rising rates of serious mental health issues and unreliability of traditional mental health treatments have spurred research into treatment forms utilizing once stigmatized and criminalized drugs. The results have been promising enough that the pharmaceutical industry around therapeutic MDMA, ketamine, psilocybin, and other psychoactive substances is tak...

Canadian Government Agency Removes Barrier for Psilocybin Therapy - Vimarsana News

Canadian Government Agency Removes Barrier for Psilocybin Therapy

In other industry news of note: Mydecine Innovations Group (CSE:MYCO) (MYCO.CNQ), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, recently announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. As part of the agreement, ProPharma Group will provide regulatory advisement as the company seeks approval from the Food and Drug Administration (FDA) for it...

Financial News Media | Canadian Government Agency Removes Barrier for Psilocybin Therapy - Vimarsana News

Financial News Media | Canadian Government Agency Removes Barrier for Psilocybin Therapy

Palm Beach, FL – December 16, 2020 – Health Canada, in a recent “breakthrough Exemption” has quietly expanded its list of who can legally possess and consume psilocybin-containing mushrooms by granting 16 health-care professionals the same exemptions it gave more than a dozen patients with terminal and mental illnesses, according to TheraPsil, a Victoria non-profit that has been behind the struggle to treat a list of mental health issues, including debilitating depression, PTSD and even terminal cancer patients.  Psilocybin is currently being studied for its potential to treat vario...

Baystreet.ca - Psychedelic Drugs Could Create a $100 Billion Investment Opportunity - Vimarsana News

Baystreet.ca - Psychedelic Drugs Could Create a $100 Billion Investment Opportunity

Psychedelic Drugs Could Create a $100 Billion Investment Opportunity With psychedelic drugs showing promise with mental health issues, investors have just begun to push into a space that could be worth up to $100 billion, according to Tania Gonsalves, analyst for Canaccord Genuity Capital Markets, as quoted by Psychedlic Spotlight. She added, “the companies that will emerge as the winners "will have deep pockets, patentable products and a well-thought-out reimbursement strategy." Helping, more cities are just beginning to decriminalize psychedelics, like psilocybin. For example, D...